>AT2G34440.1 | AGL29 (AGAMOUS-LIKE 29) transcription factor
MGRRKIKMEMVQDMNTRQVTFSKRRTGLFKKASELATLCNAELGIVVFSPGGKPFSYGKP
NLDSVAERFMREYDDSDSGDEEKSGNYRPKLKRLSERLDLLNQEVEAEKERGEKSQEKLE
SAGDERFKESIETLTLDELNEYKDRLQTVHGRIEGQVNHLQASSCLMLLSRK*
>AT5G51870.1 | AGL71 (AGAMOUS-LIKE 71) transcription factor
MVRGKIEIKKIENVTSRQVTFSKRRSGLFKKAHELSVLCDAQVAAIVFSQSGRLHEYSSS
QMEKIIDRYGKFSNAFYVAERPQVERYLQELKMEIDRMVKKIDLLEVHHRKLLGQGLDSC
SVTELQEIDTQIEKSLRIVRSRKAELYADQLKKLKEKERELLNERKRLLEEVNMHHSSKG
NTEGGHRTKHSSEVETDLFIGLPVTRL*
>AT5G51870.1 | AGL71 (AGAMOUS-LIKE 71) transcription factor
MVRGKIEIKKIENVTSRQVTFSKRRSGLFKKAHELSVLCDAQVAAIVFSQSGRLHEYSSS
QMEKIIDRYGKFSNAFYVAERPQVERYLQELKMEIDRMVKKIDLLEVHHRKLLGQGLDSC
SVTELQEIDTQIEKSLRIVRSRKAELYADQLKKLKEKERELLNERKRLLEEVNMHHSSKG
NTEGGHRTKHSSEVETDLFIGLPVTRL*
>AT5G51870.2 | AGL71 (AGAMOUS-LIKE 71) transcription factor
MVRGKIEIKKIENVTSRQVTFSKRRSGLFKKAHELSVLCDAQVAAIVFSQSGRLHEYSSS
QMEKIIDRYGKFSNAFYVAERPQVERYLQELKMEIDRMVKKIDLLEVHHRKLLGQGLDSC
SVTELQEIDTQIEKSLRIVRSRKVQTLGHKYIYNIYTHVNDVIMSSLVDLGA*
>AT5G51870.2 | AGL71 (AGAMOUS-LIKE 71) transcription factor
MVRGKIEIKKIENVTSRQVTFSKRRSGLFKKAHELSVLCDAQVAAIVFSQSGRLHEYSSS
QMEKIIDRYGKFSNAFYVAERPQVERYLQELKMEIDRMVKKIDLLEVHHRKLLGQGLDSC
SVTELQEIDTQIEKSLRIVRSRKVQTLGHKYIYNIYTHVNDVIMSSLVDLGA*
>AT4G31720.2 | TAFII15 (TBP-ASSOCIATED FACTOR II 15) RNA polymerase II transcription factor/ transcription factor
MNHGQQSGEAKHEDDAALTEFLASLMDYTPTIPDDLVEHYLAKSGFQCPDVRLIRLVAVA
TQKFVADVASDALQHCKARPAPVVKDKKQQKDKRLVLTMEDLSKALREYGVNVKHPEYFA
DSPSTGMDPATRDE*
>AT4G31720.2 | TAFII15 (TBP-ASSOCIATED FACTOR II 15) RNA polymerase II transcription factor/ transcription factor
MNHGQQSGEAKHEDDAALTEFLASLMDYTPTIPDDLVEHYLAKSGFQCPDVRLIRLVAVA
TQKFVADVASDALQHCKARPAPVVKDKKQQKDKRLVLTMEDLSKALREYGVNVKHPEYFA
DSPSTGMDPATRDE*
>AT4G31720.1 | TAFII15 (TBP-ASSOCIATED FACTOR II 15) RNA polymerase II transcription factor/ transcription factor
MNHGQQSGEAKHEDDAALTEFLASLMDYTPTIPDDLVEHYLAKSGFQCPDVRLIRLVAVA
TQKFVADVASDALQHCKARPAPVVKDKKQQKDKRLVLTMEDLSKALREYGVNVKHPEYFA
DSPSTGMDPATRDE*
>AT4G31720.1 | TAFII15 (TBP-ASSOCIATED FACTOR II 15) RNA polymerase II transcription factor/ transcription factor
MNHGQQSGEAKHEDDAALTEFLASLMDYTPTIPDDLVEHYLAKSGFQCPDVRLIRLVAVA
TQKFVADVASDALQHCKARPAPVVKDKKQQKDKRLVLTMEDLSKALREYGVNVKHPEYFA
DSPSTGMDPATRDE*
>AT4G18880.1 | AT-HSFA4A DNA binding / transcription factor
MDENNHGVSSSSLPPFLTKTYEMVDDSSSDSIVSWSQSNKSFIVWNPPEFSRDLLPRFFK
HNNFSSFIRQLNTYGFRKADPEQWEFANDDFVRGQPHLMKNIHRRKPVHSHSLPNLQAQL
NPLTDSERVRMNNQIERLTKEKEGLLEELHKQDEEREVFEMQVKELKERLQHMEKRQKTM
VSFVSQVLEKPGLALNLSPCVPETNERKRRFPRIEFFPDEPMLEENKTCVVVREEGSTSP
SSHTREHQVEQLESSIAIWENLVSDSCESMLQSRSMMTLDVDESSTFPESPPLSCIQLSV
DSRLKSPPSPRIIDMNCEPDGSKEQNTVAAPPPPPVAGANDGFWQQFFSENPGSTEQREV
QLERKDDKDKAGVRTEKCWWNSRNVNAITEQLGHLTSSERS*
>AT2G37470.1 | histone H2B putative
MAPKAAEKKPAEKKPAGKAPAEKLPKAEKKISKDAGGSEKKKKKSKKSVETYKIYIFKVL
KQVHPDVGISGKAMGIMNSFINDIFEKLAQESSKLARYNKKPTITSREIQTAVRLVLPGE
LAKHAVSEGTKAVTKFTS*
>AT1G47760.1 | AGL102 (AGAMOUS-LIKE 102) DNA binding / transcription factor
MGRRKIEIKFIEDSIERKATFSRRRNGIFKKADELAKLCNVEIAVLVISPTNIPYTYGYP
CFNDVVERIQNPSASSKLRSLMKELEQIKEFQEDLRKKQQRNLEKSNMKENVDLKLEDLV
AFKAKLEAYQAGLKRKHVEMEDLSSPSILSKNTKNKMMRTEYSSGQSKGMYEFRAFGPGF
LGTI*
>AT3G62870.1 | 60S ribosomal protein L7A (RPL7aB)
MAPKKGVKVASKKKPEKVTNPLFERRPKQFGIGGALPPKKDLSRYIKWPKSIRLQRQKRI
LKQRLKVPPALNQFTKTLDKNLATSLFKILLKYRPEDKAAKKERLLNKAQAEAEGKPAES
KKPIVVKYGLNHVTYLIEQNKAQLVVIAHDVDPIELVVWLPALCRKMEVPYCIVKGKSRL
GAVVHQKTAAALCLTTVKNEDKLEFSKILEAIKANFNDKYEEYRKKWGGGIMGSKSQAKT
KAKERVIAKEAAQRMN*
>AT1G80190.1 | PSF1 (PARTNER OF SLD FIVE 1)
MYGRKGYQLIKDFATGEKGQLKPFNSKLFDETIEECDQNHHLIQSLIRKMQQEGLDVQNN
RNADHYGALIHHLALIRNKRCLMAYVYNRAEIVRDLAWRVGLELLDLPSEIQEKLTTLEK
EYFKNHSVALKSYMGKVGIELNVDMVPPKDPYIKVRILDDIDEGIVLSDKTTNFARHSMH
FLKRTDAEPYIARGQMEELTG*
>AT1G18870.1 | ICS2 (ISOCHORISMATE SYNTHASE 2) isochorismate synthase
MASLQCSFHFLGTNPKKYNPSSIFQSYSRTSFTKLSSRVSRQRFLRCTLSMNGCEADHKA
PLGTVETRTLSTVPSPAAATERLITAVSDLKSQPPPFSSGIVRLQVPIEQKIGAIDWLHA
QNEILPRSFFSRRSDSGRPDLLQDFSSDNGSSDHNPVSVAGIGSAVFFRDLDPFSHDDWR
SIRRFLSSKSPLIRAYGGLRFDPTGKIAVEWEHFGSFYFTVPQVEFDEFGGSSMLAATVA
WDNELSWTLENAIEALQETMLQVSSVIMRLRRESLGVIVVSKNHVPSEGAYYPAVNNALE
IIKDKHSPLSKVVLARSSRIITDTDIDPIAWLARLQCEGQDAYQFCLQPPGAPAFIGNTP
ERLFHRKHLGVCSEALAATRPRGDSKVREMEIERDLLTSPKDDLEFSIVRENIREKLKTI
CDRVVVKPHKSVRKLARVQHLYSQLAGQLKREDDEFNILTALHPTPAVCGCPVEEARLLI
KQIESFDRGMYAGPIGFFGGGESEFSVGIRSALVEKGLGALIYAGTGIVSGSNPSSEWNE
LELKISQFTKSLEHESALQPIN*
>AT1G18870.1 | ICS2 (ISOCHORISMATE SYNTHASE 2) isochorismate synthase
MASLQCSFHFLGTNPKKYNPSSIFQSYSRTSFTKLSSRVSRQRFLRCTLSMNGCEADHKA
PLGTVETRTLSTVPSPAAATERLITAVSDLKSQPPPFSSGIVRLQVPIEQKIGAIDWLHA
QNEILPRSFFSRRSDSGRPDLLQDFSSDNGSSDHNPVSVAGIGSAVFFRDLDPFSHDDWR
SIRRFLSSKSPLIRAYGGLRFDPTGKIAVEWEHFGSFYFTVPQVEFDEFGGSSMLAATVA
WDNELSWTLENAIEALQETMLQVSSVIMRLRRESLGVIVVSKNHVPSEGAYYPAVNNALE
IIKDKHSPLSKVVLARSSRIITDTDIDPIAWLARLQCEGQDAYQFCLQPPGAPAFIGNTP
ERLFHRKHLGVCSEALAATRPRGDSKVREMEIERDLLTSPKDDLEFSIVRENIREKLKTI
CDRVVVKPHKSVRKLARVQHLYSQLAGQLKREDDEFNILTALHPTPAVCGCPVEEARLLI
KQIESFDRGMYAGPIGFFGGGESEFSVGIRSALVEKGLGALIYAGTGIVSGSNPSSEWNE
LELKISQFTKSLEHESALQPIN*
>AT1G18870.2 | ICS2 (ISOCHORISMATE SYNTHASE 2) isochorismate synthase
MNGCEADHKAPLGTVETRTLSTVPSPAAATERLITAVSDLKSQPPPFSSGIVRLQVPIEQ
KIGAIDWLHAQNEILPRSFFSRRSDSGRPDLLQDFSSDNGSSDHNPVSVAGIGSAVFFRD
LDPFSHDDWRSIRRFLSSKSPLIRAYGGLRFDPTGKIAVEWEHFGSFYFTVPQVEFDEFG
GSSMLAATVAWDNELSWTLENAIEALQETMLQVSSVIMRLRRESLGVIVVSKNHVPSEGA
YYPAVNNALEIIKDKHSPLSKVVLARSSRIITDTDIDPIAWLARLQCEGQDAYQFCLQPP
GAPAFIGNTPERLFHRKHLGVCSEALAATRPRGDSKVREMEIERDLLTSPKDDLEFSIVR
ENIREKLKTICDRVVVKPHKSVRKLARVQHLYSQLAGQLKREDDEFNILTALHPTPAVCG
CPVEEARLLIKQIESFDRGMYAGPIGFFGGGESEFSVGIRSALVEKGLGALIYAGTGIVS
GSNPSSEWNELELKISQFTKSLEHESALQPIN*
>AT1G18870.2 | ICS2 (ISOCHORISMATE SYNTHASE 2) isochorismate synthase
MNGCEADHKAPLGTVETRTLSTVPSPAAATERLITAVSDLKSQPPPFSSGIVRLQVPIEQ
KIGAIDWLHAQNEILPRSFFSRRSDSGRPDLLQDFSSDNGSSDHNPVSVAGIGSAVFFRD
LDPFSHDDWRSIRRFLSSKSPLIRAYGGLRFDPTGKIAVEWEHFGSFYFTVPQVEFDEFG
GSSMLAATVAWDNELSWTLENAIEALQETMLQVSSVIMRLRRESLGVIVVSKNHVPSEGA
YYPAVNNALEIIKDKHSPLSKVVLARSSRIITDTDIDPIAWLARLQCEGQDAYQFCLQPP
GAPAFIGNTPERLFHRKHLGVCSEALAATRPRGDSKVREMEIERDLLTSPKDDLEFSIVR
ENIREKLKTICDRVVVKPHKSVRKLARVQHLYSQLAGQLKREDDEFNILTALHPTPAVCG
CPVEEARLLIKQIESFDRGMYAGPIGFFGGGESEFSVGIRSALVEKGLGALIYAGTGIVS
GSNPSSEWNELELKISQFTKSLEHESALQPIN*
>AT5G40370.1 | glutaredoxin putative
MAMQKAKEIVNSESVVVFSKTYCPYCVRVKELLQQLGAKFKAVELDTESDGSQIQSGLAE
WTGQRTVPNVFIGGNHIGGCDATSNLHKDGKLVPLLTEAGAIAGKTATTSA*
>AT5G40370.1 | glutaredoxin putative
MAMQKAKEIVNSESVVVFSKTYCPYCVRVKELLQQLGAKFKAVELDTESDGSQIQSGLAE
WTGQRTVPNVFIGGNHIGGCDATSNLHKDGKLVPLLTEAGAIAGKTATTSA*
>AT5G40370.2 | glutaredoxin putative
MDSIMCVSSWKFYTMNDSWMYLDAFVYQWMILSYLIGNFSGICSKTYCPYCVRVKELLQQ
LGAKFKAVELDTESDGSQIQSGLAEWTGQRTVPNVFIGGNHIGGCDATSNLHKDGKLVPL
LTEAGAIAGKTATTSA*
>AT5G40370.2 | glutaredoxin putative
MDSIMCVSSWKFYTMNDSWMYLDAFVYQWMILSYLIGNFSGICSKTYCPYCVRVKELLQQ
LGAKFKAVELDTESDGSQIQSGLAEWTGQRTVPNVFIGGNHIGGCDATSNLHKDGKLVPL
LTEAGAIAGKTATTSA*
>AT3G22880.1 | DMC1 (DISRUPTION OF MEIOTIC CONTROL 1) ATP binding / DNA binding / DNA-dependent ATPase/ damaged DNA binding / nucleoside-triphosphatase/ nucleotide binding / protein binding
MMASLKAEETSQMQLVEREENDEDEDLFEMIDKLIAQGINAGDVKKLQEAGIHTCNGLMM
HTKKNLTGIKGLSEAKVDKICEAAEKIVNFGYMTGSDALIKRKSVVKITTGCQALDDLLG
GGIETSAITEAFGEFRSGKTQLAHTLCVTTQLPTNMKGGNGKVAYIDTEGTFRPDRIVPI
AERFGMDPGAVLDNIIYARAYTYEHQYNLLLGLAAKMSEEPFRILIVDSIIALFRVDFTG
RGELADRQQKLAQMLSRLIKIAEEFNVAVYMTNQVIADPGGGMFISDPKKPAGGHVLAHA
ATIRLLFRKGKGDTRVCKVYDAPNLAEAEASFQITQGGIADAKD*
>AT1G24706.1 | unknown protein
MSLPLLECKYVTEEFVREGKNGNYGTKLPSSVPMLRFLYELSWILVRGELPIQSCKAVLE
GVEFLDKPSREELASCFADVVTQIAQDLTMSGDQRSRLIKLAKWLVESQTVPQRLFQERC
EEEFLWEADMVKIKAQDLKGKEVRLNTRLLYQQTKFNLLREESEGYAKLATLLCRGSASS
SHNASAATMGIIKSLIGHFDLDPNRVFDIVLDCFELEQDYDTFLNLIPIFPKSHASQILG
FKFQYYQRLEVNSPVPVGLYKLTALLVKEEFINLESIYAHLLPKDEEVFEDYNVSSAKRF
EEANKIGKINLAATGKDLMEDEKQGDVTVDLFAALDMESEAVTERLPELENNQTLGLLNG
FLSVDDWYHANILFERLAPLNPVAHDQICSGLFRLIEKSITHSYRIARQTRFQSSSSAST
VKLTPTANTTANRTYLDLPKEVFQMLVTVGPYLYRNTQLLQKICRVLRAYYLSALDLVRD
GSNQEGSAYEVSRGHLKEVRLRVEEALGTCLLPSLQLVPANPAVGHEIWEVMSLLPYEAR
YRLYGEWEKDDEQNPLLLAARQVAKLDTRRILKRLAKENLKQLGRMVAKLAHANPMTVLR
TIVNQIEAYRDMIAPVVDAFKYLTQLEYDILEYVVIERLAQSGRDKLKDDGINLSDWLQS
LASFWGHLCKKYPSMELRGLFQYLVNQLKRGQGIELVLLQELVQQMANVQYTENLTEDQL
DAMAGSETLRYHATSFGMMRNNKALIKSSNRLRDSLLPNDEPKLAIPLLLLIAQHRSLVV
VNADAPYIKMVTEQFDRCHGILLQYVDFLSSAVSPTTAYARLVPSLDELVHTYHLEAEVA
FLVFRPVMRLFKCRRNGDVSWPLDSGESMDADSEISESESSMILDVGTSEKAVTWSDVLD
TVRTMLPSKAWNSLSPDLYATFWGLTLYDLHVPRNRYESEISKQHTALKTLEEVADNSSS
AITKRKKEKERIQESLDRLTGELKKHEEHVASVRRRLSREKDTWLSSCPDTLKINMEFLQ
RCIFPRCTFSMADSVYCAMFVNMLHSLGTPFFNTVNHIDVLICKTLQPMICCCTEYEVGR
LGRFLFETLKIAYHWKSKESVYEHECGNMPGFAVYYRYPNSQRVTFGQFVKVHWKWSGRI
TRLLIQCLESNEYMEIRNALIMLTKISGVFPVTRKTGINLEKRATKIKNDEREDLKVLAT
GVGAALSARKPHWVTDEEFSMGFLELKAPPVHTPKHASSQNGLLVGVSQGEPTGERATVN
QQPESGGLGKDQMLKTKPLDGRTESIPSKSDQGHLKSKGGNPLDSQPSISKKSMEQKETD
ETPRISDENPVKPASKYSEAELKASSKRGASVNKSAKQDFGKDDGKSGKAIGRTSTADKD
LNYLESRQSGLTKALSSTAANGSIATGSSKVKDDGAEALDAQKQSSRTVHSPRHEIVTSV
RSSDRLQKRANAVEDSERISKRRKGDAEHKEHDSEPRSSDRDRSVEARLDLNKTVTDDQS
THRDQDRSKDKGYERQDRDHRERVDRSDKPRGDDVEKARDKSLERHGRERSVEKGLDKGT
TRSYDRNKDERNKDDRSKLRHSEASLEKSHPDDHFHSQGLPPPPPLPPNIIPHSMAAKED
LERRAGGARHSQRLSPRHEEREKRRSEENLSVSVDDAKRRRDDDIRDRKRDDRETITVKG
EEREREREREREREKSLPLKEDFEASKRRKLKREQQVPSAEPGEYSPMPHHSSLSTSMGP
SSYEGRERKSSSMIQHGGYLEEPSIRLLGKEASSKMARRDPDPIYDREWEDDKRRAERKR
RDRK*
>AT2G16740.1 | UBC29 (ubiquitin-conjugating enzyme 29) ubiquitin-protein ligase
MATRRILKELKELQRDPPVSCSAGPTGEDMFHWQATIMGPNESPYSGGVFLVNIHFPPDY
PFKPPKVVFRTKVFHPNINSNGNICLDILKDQWSPALTISKVLLSICSLLTDPNPDDPLV
PEIAHIYKTDKTKYEAMARSWTQKYALF*
>AT3G30842.1 | PDR10 (PLEIOTROPIC DRUG RESISTANCE 10) ATP binding / ATPase/ nucleoside-triphosphatase/ nucleotide binding
MAHYRVSSEVENIMNRDRSHRKNEEEDEEEALKLAAMEKLQRLPTYDRARKAVLKGITGG
FKEIDMKDLGLAERRELFDRVMTMDDEDWHGEYLRRLKSRFDRVSLHLPTIEVRFEDLNV
TAEAYAGSKTVPTVLNSYVNLLKGIGTKIRVLPDRKKRISILNDVSGIIKPGRLTLLLGP
PGSGKSTLLKALSGKTETGLRSTGKVTYNGHELHEFVPERTAGYIDQYDVHLPDLTVRET
LKFSAKCQGVGTGYDMLAELLRREKDLNIKPDPYLDALMKASVIKGHKEYVVTDYVLKVL
GLEICADTIVGNHMKRGISGGQKKRVTTGEMLVGPVGAFFMDNISDGLDSSTTFQIVKSI
KQMIHVFDKTALISLLQPPPETFELFDDVIILGEGHIVYQGPREDVLEFFEFMGFKCPER
KGIADYLQEILSKKDQEQYWANPELPYRYVTAKKFEEGFKIHHFGRAMRSQLATPFDRLK
NHRAALTRTTYGASKLELLKACLERESILMKRNLRTFVLKSLQLIINAILIGVVFWQQKN
YPSTVEDGIIYMGAIYLEVQMIVFSGFFELPMTIDKLPVFYKQRHFSFYPSWAFSLPTSI
ITFPLSFVEVFIVVLITYFTIGYDLTVPSFLKHYLVLALCGQMSYGLFRCIAAVTRNHVV
SNTMGCLAVMWLMTFSGYVLSRNQVHKWLTWAYWTSPMMYIQTAVSVNEFRSESWKDVIS
KKPFFKFSTSHFKDIKLNRVVYDFQGLGVAVLKSREYGISKTAVLPDEREEADSNNTTGR
DYTGTTMERFFDRVVTTRTCNDKKLRIPFKPLYMTFENITYSVDTPKEMKEKGIRENKLV
LLNGLSGAFRPGVLTALMGVSGAGKTTLMDVLAGRKNTGYIQGEIYVSGFPKKQDSFARV
SGYCEQSDIHSPLLTVYESLLYSAWLRLPPDIDTHTREVMELIELKALREMLVGYVGISG
LSTEQRKRMTIAVELVANPSILFMDEPTSGLDARAAAIVMRTVRNTVDTGRTVVCTIHQP
SIDIFESFDELFLLTRGGEEIYVGPIGHHSSQLIEYFEGIRGVGKIKEGYNPATWALEVT
TRAQEDVLGVTFAQVYKKSNLYRRNKDLIKELNNIPPHAQDIHFSTKYSQSYLSQFQACL
WKQHKSYWRNVPYNAVRFSFGAAVGIMYGIIFWSLGKRKGTRQDIFNSVGAMSTVVGFLS
SQSAATVRPVVIAERTVFYREAGAGMYSALPYAFSQVIIEIPYTMAQACIYGVIVYGMIG
YEWTASKFFLNIFFTFISILYSIYTGIMVISVSPNQEIASILNGVISTSWNVFSGFTIPR
PRMHVWLRWFTYVCPGWWGLYGLTIAQYGDVETRLDTGETVVEFMKNYYGYEYNFLWVVS
LTLIAFSMFFVFIYAFSVKILNFQKR*
>AT3G62770.1 | AtATG18a
MATVSSSSWPNPNPNPDSTSASDSDSTFPSHRDRVDEPDSLDSFSSMSLNSDEPNQTSNQ
SPLSPPTPNLPVMPPPSVLHLSFNQDHACFAVGTDRGFRILNCDPFREIFRRDFDRGGGV
AVVEMLFRCNILALVGGGPDPQYPPNKVMIWDDHQGRCIGELSFRSDVRSVRLRRDRIIV
VLEQKIFVYNFSDLKLMHQIETIANPKGLCAVSQGVGSMVLVCPGLQKGQVRIEHYASKR
TKFVMAHDSRIACFALTQDGHLLATASSKGTLVRIFNTVDGTLRQEVRRGADRAEIYSLA
FSSNAQWLAVSSDKGTVHVFGLKVNSGSQVKDSSRIAPDATPSSPSSSLSLFKGVLPRYF
SSEWSVAQFRLVEGTQYIAAFGHQKNTVVILGMDGSFYRCQFDPVNGGEMSQLEYHNCLK
PPSVF*
>AT3G62770.1 | AtATG18a
MATVSSSSWPNPNPNPDSTSASDSDSTFPSHRDRVDEPDSLDSFSSMSLNSDEPNQTSNQ
SPLSPPTPNLPVMPPPSVLHLSFNQDHACFAVGTDRGFRILNCDPFREIFRRDFDRGGGV
AVVEMLFRCNILALVGGGPDPQYPPNKVMIWDDHQGRCIGELSFRSDVRSVRLRRDRIIV
VLEQKIFVYNFSDLKLMHQIETIANPKGLCAVSQGVGSMVLVCPGLQKGQVRIEHYASKR
TKFVMAHDSRIACFALTQDGHLLATASSKGTLVRIFNTVDGTLRQEVRRGADRAEIYSLA
FSSNAQWLAVSSDKGTVHVFGLKVNSGSQVKDSSRIAPDATPSSPSSSLSLFKGVLPRYF
SSEWSVAQFRLVEGTQYIAAFGHQKNTVVILGMDGSFYRCQFDPVNGGEMSQLEYHNCLK
PPSVF*
>AT3G62770.3 | AtATG18a
MATVSSSSWPNPNPNPDSTSASDSDSTFPSHRDRVDEPDSLDSFSSMSLNSDEPNQTSNQ
SPLSPPTPNLPVMPPPSVLHLSFNQDHACFAVGTDRGFRILNCDPFREIFRRDFDRGGGV
AVVEMLFRCNILALVGGGPDPQYPPNKVMIWDDHQGRCIGELSFRSDVRSVRLRRDRIIV
VLEQKIFVYNFSDLKLMHQIETIANPKGLCAVSQGVGSMVLVCPGLQKGQVRIEHYASKR
TKFVMAHDSRIACFALTQDGHLLATASSKGTLVRIFNTVDGTLRQEVRRGADRAEIYSLA
FSSNAQWLAVSSDKGTVHVFGLKVNSGSQVKDSSRIAPDATPSSPSSSLSLFKGVLPRYF
SSEWSVAQFRLVEGTQYIAAFGHQKNTVVILGMDGR*
>AT3G62770.3 | AtATG18a
MATVSSSSWPNPNPNPDSTSASDSDSTFPSHRDRVDEPDSLDSFSSMSLNSDEPNQTSNQ
SPLSPPTPNLPVMPPPSVLHLSFNQDHACFAVGTDRGFRILNCDPFREIFRRDFDRGGGV
AVVEMLFRCNILALVGGGPDPQYPPNKVMIWDDHQGRCIGELSFRSDVRSVRLRRDRIIV
VLEQKIFVYNFSDLKLMHQIETIANPKGLCAVSQGVGSMVLVCPGLQKGQVRIEHYASKR
TKFVMAHDSRIACFALTQDGHLLATASSKGTLVRIFNTVDGTLRQEVRRGADRAEIYSLA
FSSNAQWLAVSSDKGTVHVFGLKVNSGSQVKDSSRIAPDATPSSPSSSLSLFKGVLPRYF
SSEWSVAQFRLVEGTQYIAAFGHQKNTVVILGMDGR*
>AT4G26230.1 | 60S ribosomal protein L31 (RPL31B)
MSEKKGRKEEVVTREYTINLHRRLHSCTFKKKAPKAIKEIRKFAEKEMGTKDVRVDVKLN
KQIWSKGIRGPPRRIRVRVARKRNDDEDAKEEFFSLVTVAEIPAEGLSGLGTKIIEEED*
>AT5G16980.1 | NADP-dependent oxidoreductase putative
MGGVQCYHLTHEHFKIQHTDVPLSYYTGLLGMPGMTAYVGFYEICSPKKGETVYVSAASG
AVGQLVGQFAKMMGCYVVGSAGSKEKVDLLKTKFGFDYAFNYKEEPDLSAALKRCFPNGI
DIYFENVGGKMLDAVLMNMNMHGRIAVCGMISQYNLENQEGVHNLSNIIYKRIRIQGFVV
SDFYDEYSKFLEFLHPHIKEGKITYVEDVADGLEKGPEALVGLFHGKNVGKQVVVIARE*